The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 301–400 of 999
Ramos, F., Spanish Group for Myelodysplastic Syndromes (GESMD), Robledo, C., Izquierdo-García, F. M., Suárez‐Vilela, D., Benito, R., Fuertes, M., Insunza, A., Barragán, E., Rey, M. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9026 · Cited by 49
Anande, G., Deshpande, N., Mareschal, S., Batcha, A. M. N., Hampton, H. R., Herold, T., Lehmann, S., Wilkins, M. R., Wong, J. W. H., Unnikrishnan, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0184 · Cited by 49
Stengel, A., Shahswar, R., Haferlach, T., Walter, W., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003007 · Cited by 50
Self-citationTao, Y., Xu, L., Lu, J., Cao, L., Li, Z., Hu, S., Wang, N., Du, X., Sun, L., Zhao, W., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-182 · Cited by 48
Qiu, J., Zhou, B., Thol, F. R., Zhou, Y., Chen, L., Shao, C., DeBoever, C., Hou, J., Li, H., Chaturvedi, A., et al. (2016) · RNA · doi:10.1261/rna.056101.116 · Cited by 48
Rautenberg, C., Pechtel, S., Hildebrandt, B., Betz, B., Dienst, A., Nachtkamp, K., Kondakci, M., Geyh, S., Wieczorek, D., Haas, R. R., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.011 · Cited by 48
Pericole, F. V., Lazarini, M., de Paiva, L. B., Duarte, A. S. S., Ferro, K. P., Niemann, F. S., Roversi, F. M., & Saad, S. T. O. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00016 · Cited by 47
QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer
Wang, J.-Z., Fu, X., Fang, Z., Liu, H., Zong, F.-Y., Zhu, H. M., Yu, Y.-F., Zhang, X.-Y., Wang, S.-F., Huang, Y., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa063 · Cited by 47
Scharenberg, C., Giai, V., Pellagatti, A., Saft, L., Dimitriou, M., Jansson, M., Jädersten, M., Grandien, A., Douagi, I., Neuberg, D. S., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.152025 · Cited by 47
Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable
Bose, P., Nazha, A., Komrokji, R. S., Patel, K. P., Pierce, S. A., Al‐Ali, N., Sochacki, A. L., Shaver, A. C., Ma, W., Su, X., et al. (2018) · Blood · doi:10.1182/blood-2018-05-848473 · Cited by 47
Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 49
Zhang, L., Padron, E., & Lancet, J. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.006 · Cited by 47
Aplastic anemia and clonal evolution: germ line and somatic genetics
Shimamura, A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.74 · Cited by 48
The Molecular Pathology of Myelodysplastic Syndrome
Haferlach, T. (2018) · Pathobiology · doi:10.1159/000488712 · Cited by 52
Self-citationClonal Hematopoiesis and Its Impact on Cardiovascular Disease
Sano, S., Wang, Y., & Walsh, K. X. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0871 · Cited by 50
Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Hahn, C. N., Venugopal, P., Scott, H. S., & Hiwase, D. (2014) · Immunological Reviews · doi:10.1111/imr.12241 · Cited by 46
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Cogle, C. R., Scott, B. L., Boyd, T. E., & Garcia‐Manero, G. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0165 · Cited by 46
Bartels, S., Schipper, E., Hasemeier, B., Kreipe, H. H., & Lehmann, U. (2016) · Oncotarget · doi:10.18632/oncotarget.8310 · Cited by 46
Kosmider, O., Passet, M., Santini, V., Platzbecker, U., Andrieu, V., Zini, G., Beyne‐Rauzy, O., Guerci‐Bresler, A., Masala, E., Balleari, E., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142695 · Cited by 46
Robin, M., Porcher, R., Zinke-Cerwenka, W., van Biezen, A., Volin, L., Mufti, G. J., Craddock, C., Finke, J., Richard, C., Passweg, J. R., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.266 · Cited by 46
Stengel, A., Kern, W., Meggendorfer, M., Nadarajah, N., Perglerová, K., Haferlach, T., & Haferlach, C. (2017) · Leukemia · doi:10.1038/leu.2017.239 · Cited by 46
Self-citationCBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1
Belizaire, R., Koochaki, S., Udeshi, N. D., Vedder, A., Sun, L., Svinkina, T., Hartigan, C. R., McConkey, M. E., Kovalcik, V., Bizuayehu, A., et al. (2021) · Blood · doi:10.1182/blood.2020006528 · Cited by 49
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish
Weinreb, J. T., Gupta, V., Sharvit, E., Weil, R., & Bowman, T. V. (2021) · Haematologica · doi:10.3324/haematol.2020.257246 · Cited by 43
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Bahaj, W., Kewan, T., Gurnari, C., Durmaz, A., Ponvilawan, B., Pandit, I., Kubota, Y., Ogbue, O. D., Zawit, M., Madanat, Y., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01480-y · Cited by 45
Self-citationSomatic PHF6 mutations in 1760 cases with various myeloid neoplasms
Mori, T., Nagata, Y., Makishima, H., Sanada, M., Shiozawa, Y., Kon, A., Yoshizato, T., Sato‐Otsubo, A., Kataoka, K., Shiraishi, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.212 · Cited by 45
Self-citationAguilera-Diaz, A., Vázquez, I., Ariceta, B., Mañú, A., Blasco‐Iturri, Z., Palomino‐Echeverría, S., Larráyoz, M. J., García‐Sánz, R., Prieto-Conde, I., Chillón, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227986 · Cited by 45
Yokota, A., Huo, L., Lan, F., Wu, J., & Huang, G. (2020) · PubMed Central · doi:10.14348/molcells.2019.0252 · Cited by 45
Calvo, X., García-Gisbert, N., Párraga, I., Gibert, J., Florensa, L., Andrade‐Campos, M., Merchán, B., Garcia-Ávila, S., Montesdeoca, S., Fernández‐Rodríguez, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002206 · Cited by 45
MicroRNA21 and the various types of myeloid leukemia
Panagal, M., R., S. K. S., Sivakurunathan, P., Biruntha, M., Karthigeyan, M., Gopinathe, V., Sivakumare, P., & Sekar, D. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0025-2 · Cited by 44
Woerner, J., Huang, Y., Hütter, S., Gurnari, C., Sánchez, J. M. H., Wang, J., Huang, Y., Schnabel, D., Aaby, M., Xu, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28678-x · Cited by 45
Self-citationClonal hematopoiesis: Pre-cancer PLUS
Silver, A. J., & Jaiswal, S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.003 · Cited by 46
The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia
Zheng, G., Chen, P., Pallavajjalla, A., Haley, L. M., Gondek, L. P., Dezern, A. E., Ling, H., Marchi, F. D., Lin, M., & Gocke, C. D. (2019) · American Journal of Hematology · doi:10.1002/ajh.25592 · Cited by 42
Cao, Y., He, Y., Zhang, S., Liu, Z., Zhai, W., Ma, Q., Pang, A., Wei, J.-L., Yang, D., Huang, Y., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.09.001 · Cited by 44
Gao, Y., Jia, M.-N., Mao, Y., Cai, H., Jiang, X., Cao, X., Zhou, D., & Li, J. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab172 · Cited by 43
Wu, J., Zhang, Y., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Jia, Y., Li, C., Wang, H., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00328-4 · Cited by 46
Cohesin Mutations in Myeloid Malignancies
Fisher, J. B., McNulty, M., Burke, M. J., Crispino, J. D., & Rao, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.02.006 · Cited by 52
Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Díez‐Campelo, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22157 · Cited by 45
Concordance for clonal hematopoiesis is limited in elderly twins
Fabre, M. A., McKerrell, T., Zwiebel, M., Vijayabaskar, M. S., Park, N., Wells, P. M., Rad, R., Deloukas, P., Small, K. S., Steves, C. J., et al. (2019) · Blood · doi:10.1182/blood.2019001807 · Cited by 43
The functional mechanisms of mutations in myelodysplastic syndrome
Nagata, Y., & Maciejewski, J. P. (2019) · Leukemia · doi:10.1038/s41375-019-0617-3 · Cited by 42
Self-citationLarge-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Feusier, J. E., Arunachalam, S., Tashi, T., Baker, M. J., Vansant-Webb, C. H., Ferdig, A., Welm, B. E., Rodríguez-Flores, J. L., Ours, C., Jorde, L. B., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0094 · Cited by 45
The Impact of Epigenetic Modifications in Myeloid Malignancies
Venney, D., Mohd-Sarip, A., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095013 · Cited by 46
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML
Wheeler, E. C., Martin, B. J. E., Doyle, W. C., Neaher, S., Conway, C. A., Pitton, C. N., Gorelov, R. A., Donahue, M. K., Jann, J. C., Abdel-Wahab, O. I., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2774 · Cited by 42
Chesnais, V., Renneville, A., Toma, A., Lambert, J., Passet, M., Dumont, F., Chevret, S., Lejeune, J., Raimbault, A., Stamatoullas, A., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640128 · Cited by 47
Reilly, B. M., Tanaka, T. N., Diep, D. H., Yeerna, H., Tamayo, P., Zhang, K., & Bejar, R. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000192 · Cited by 43
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42
CETLAM group, Cabezón, M., Malinverni, R., Bargay, J., Xicoy, B., Marcé, S., Garrido, A., Tormo, M., Arenillas, L., Coll, R., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01002-y · Cited by 42
Lee, E.-J., Podoltsev, N. A., Gore, S. D., & Zeidan, A. M. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.004 · Cited by 42
Mohamedali, A. M., Gäken, J. A., Ahmed, M., MALIK, F., Smith, A., Best, S., Mian, S. A., Gaymes, T. J., Ireland, R. M., Kulasekararaj, A. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.110 · Cited by 42
Robertson, A. L., Avagyan, S., Gansner, J. M., & Zon, L. I. (2016) · FEBS Letters · doi:10.1002/1873-3468.12415 · Cited by 44
Palomo, L., Ibáñez, M., Abáigar, M., Vázquez, I., Álvarez, S., Cabezón, M., Tazón‐Vega, B., Rapado, I., Fuster‐Tormo, F., Cervera, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16175 · Cited by 44
New Approaches to Myelodysplastic Syndrome Treatment
Bazinet, A., & Bravo, G. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00965-1 · Cited by 40
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C., Heiser, D., & Greenberg, P. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001934 · Cited by 40
Behrens, K., Triviai, I., Schwieger, M., Tekin, N. S., Alawi, M., Spohn, M., Indenbirken, D., Ziegler, M., Müller, U., Alexander, W. S., et al. (2016) · Blood · doi:10.1182/blood-2015-09-668129 · Cited by 40
Jawhar, M., Döhner, K., Kreil, S., Schwaab, J., Shoumariyeh, K., Meggendorfer, M., Span, L. L. F., Fuhrmann, S., Naumann, N., Horny, H.-P., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0346-z · Cited by 43
Self-citationEmerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology
Vivet-Noguer, R., Tarin, M., Roman‐Roman, S., & Alsafadi, S. (2019) · Cancers · doi:10.3390/cancers11071019 · Cited by 43
van de Loosdrecht, A. A., Kern, W., Porwit‐MacDonald, A., Valent, P., Kordasti, S. Y., Cremers, E. M. P., Alhan, C., Duetz, C., Dunlop, A. S., Hobo, W. A., et al. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22044 · Cited by 40
Self-citationXu, F., Wu, L., Chang, C., He, Q., Zhang, Z., Liu, L., Shi, W.-H., Guo, J., Zhu, Y., Zhao, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms9806 · Cited by 41
Hansen, J. W., Westman, M. K., Sjø, L. D., Saft, L., Kristensen, L. S., Ørskov, A. D., Treppendahl, M. B., Andersen, M. K., & Grønbæk, K. (2016) · American Journal of Hematology · doi:10.1002/ajh.24554 · Cited by 42
Huber, S., Haferlach, T., Meggendorfer, M., Hütter, S., Hoermann, G., Baer, C. R., Kern, W., & Haferlach, C. (2022) · Leukemia · doi:10.1038/s41375-022-01728-5 · Cited by 42
Self-citationMolecular patterns identify distinct subclasses of myeloid neoplasia
Kewan, T. Z., Durmaz, A., Bahaj, W., Gurnari, C., Terkawi, L., Awada, H., Ogbue, O., Ahmed, R., Pagliuca, S., Awada, H. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38515-4 · Cited by 37
Self-citationBoddu, P. C., Gupta, A. K., Roy, R., Avalos, B. D. L. P., Olazabal‐Herrero, A., Neuenkirchen, N., Zimmer, J. T., Chandhok, N. S., King, D. P., Nannya, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.032 · Cited by 41
Self-citationGuièze, R., Damaj, G. L., Pereira, B., Robin, M., Chevallier, P., Michallet, M., Vigouroux, S., Beguin, Y. P., Blaise, D., Cheikh, J. E., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.037 · Cited by 39
Reinig, E. F., Yang, F., Traer, E. A., Arora, R., Brown, S., Rattray, R. M., Braziel, R. M., Fan, G., Press, R. D., & Dunlap, J. B. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw016 · Cited by 41
Popp, H. D., Naumann, N., Brendel, S., Henzler, T., Weiß, C., Hofmann, W., & Fabarius, A. C. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.03.011 · Cited by 40
Preclinical modeling of myelodysplastic syndromes
Rouault‐Pierre, K., Mian, S. A., Goulard, M., Abarrategi, A., Tullio, A. D., Smith, A., Mohamedali, A., Best, S., Nloga, A.-M., Kulasekararaj, A. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.172 · Cited by 43
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
Dombret, H., & Itzykson, R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.45 · Cited by 43
Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications
Hartmann, L., & Metzeler, K. H. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22756 · Cited by 42
Jiang, L., Luo, Y., Zhu, S., Wang, L., Ma, L., Zhang, H., Shen, C., Yang, W., Ren, Y., Zhou, X., et al. (2019) · Cancer Science · doi:10.1111/cas.14270 · Cited by 39
Emerging treatment options for patients with high-risk myelodysplastic syndrome
Bewersdorf, J. P., Carraway, H. E., & Prébet, T. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720955006 · Cited by 39
PHF6 Mutations in Hematologic Malignancies
Kurzer, J. H., & Weinberg, O. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704471 · Cited by 41
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar, R. L. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0270-5 · Cited by 40
Multistep tumorigenesis in peripheral T cell lymphoma
Sakata‐Yanagimoto, M. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1738-8 · Cited by 38
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes
Itzykson, R., Kosmider, O., & Fenaux, P. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.01.001 · Cited by 40
DNA methylation in normal and malignant hematopoiesis
Celik, H., Kramer, A. C., & Challen, G. A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1957-7 · Cited by 39
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson, M., McLornan, D. P., Karimi, M., Dimitriou, M., Jansson, M., Azenkoud, A. B., Jädersten, M., Lindberg, G., Abdulkadir, H., Kulasekararaj, A. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7899 · Cited by 39
Jiang, Y., Eveillard, J., Couturier, M., Soubise, B., Chen, J., Gao, S., Basinko, A., Morel, F., Douet‐Guilbert, N., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13030481 · Cited by 41
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins
Yoshimi, A., & Abdel-Wahab, O. I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0131 · Cited by 39
Hwang, W. C., Park, K., Park, S., Cheon, N. Y., Lee, J. Y., Hwang, T., Lee, S., Lee, J.-M., Ju, M. K., Lee, J. R., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02228-4 · Cited by 38
Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing
Kim, J., Hwang, B., Park, S. N., Huh, S., Im, K., Choi, S., Chung, H. Y., Huh, J.-R., Seo, E., Lee, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167641 · Cited by 38
Gerritsen, M., Yi, G., Tijchon, E. J. H., Kuster, J., Schuringa, J. J., Martens, J. H. A., & Vellenga, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024422 · Cited by 39
TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 39
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia
Awad, S. A., Kankainen, M., & Mustjoki, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894652 · Cited by 39
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 40
Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease
Martignoles, J., Delhommeau, F., & Hirsch, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123850 · Cited by 46
Vegivinti, C. T. R., Keesari, P. R., Veeraballi, S., Maia, C., Mehta, A. K., Lavu, R. R., Thakur, R., Tella, S. H., Patel, R. J., Kakumani, V. K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00422-1 · Cited by 43
Bennett, J. M. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.005 · Cited by 36
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells
Liu, T., Krysiak, K., Shirai, C. L., Kim, S. P., Shao, J., Ndonwi, M., & Walter, M. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170470 · Cited by 36
Bewersdorf, J. P., Ardasheva, A., Podoltsev, N. A., Singh, A., Biancon, G., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100587 · Cited by 37
Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà, E., Nicolosi, M., Ferri, V., Favini, C., Gaïdano, G., & Patriarca, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186862 · Cited by 36
Flach, J., Jann, J.-C., Knaflic, A., Riabov, V., Streuer, A., Altrock, E., Xu, Q., Schmitt, N., Obländer, J., Nowak, V., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.254193 · Cited by 36
Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells
Mian, S., Abarrategi, A., Kong, K., Rouault-Pierre, K., Wood, H., Oedekoven, C. A., Smith, A., Batsivari, A., Ariza-McNaughton, L., Johnson, P., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0161 · Cited by 29
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Roloff, G. W., & Griffiths, E. A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020206 · Cited by 36
The TET2 interactors and their links to hematological malignancies
Pan, F., Weeks, O. I., Yang, F., & Xu, M. (2015) · IUBMB Life · doi:10.1002/iub.1389 · Cited by 36
Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
Nazha, A., Seastone, D. J., Radivoyevitch, T., Przychodzen, B. P., Carraway, H. E., Patel, B. J., Carew, J. S., Makishima, H., Sekeres, M. A., & Maciejewski, J. P. (2015) · Haematologica · doi:10.3324/haematol.2015.130112 · Cited by 36
Stahl, M. F., Bewersdorf, J. P., Xie, Z., Porta, M. G. D., Komrokji, R. S., Xu, M. L., Abdel-Wahab, O. I., Taylor, J., Steensma, D. P., Starczynowski, D. T., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101128 · Cited by 35
Meggendorfer, M., de Albuquerque, A., Nadarajah, N., Alpermann, T., Kern, W., Steuer, K., Perglerová, K., Haferlach, C., Schnittger, S., & Haferlach, T. (2015) · Haematologica · doi:10.3324/haematol.2015.127985 · Cited by 37
Self-citationMesenchymal stromal cells in myeloid malignancies
Schroeder, T. A., Geyh, S., Germing, U., & Haas, R. R. (2016) · Blood Research · doi:10.5045/br.2016.51.4.225 · Cited by 38
We skip to work: alternative splicing in normal and malignant myelopoiesis
Wong, A. C. H., Rasko, J. E. J., & Wong, J. J. L. (2018) · Leukemia · doi:10.1038/s41375-018-0021-4 · Cited by 35
Mutations and karyotype predict treatment response in myelodysplastic syndromes
Idossa, D. W., Lasho, T. L., Finke, C. M., Ketterling, R. P., Patnaik, M. M., Pardanani, A. D., Gangat, N., & Tefferi, A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25267 · Cited by 35
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
